GlycoMimetics (GlycoMimetics) Cash-to-Debt : 51.66 (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is GlycoMimetics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. GlycoMimetics's cash to debt ratio for the quarter that ended in Dec. 2023 was 51.66.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, GlycoMimetics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for GlycoMimetics's Cash-to-Debt or its related term are showing as below:

GLYC' s Cash-to-Debt Range Over the Past 10 Years
Min: 43.67 Med: 5026.05 Max: No Debt
Current: 51.66

During the past 13 years, GlycoMimetics's highest Cash to Debt Ratio was No Debt. The lowest was 43.67. And the median was 5026.05.

GLYC's Cash-to-Debt is ranked better than
72.97% of 1539 companies
in the Biotechnology industry
Industry Median: 6.5 vs GLYC: 51.66

GlycoMimetics Cash-to-Debt Historical Data

The historical data trend for GlycoMimetics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

GlycoMimetics Cash-to-Debt Chart

GlycoMimetics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

43.67

48.61

47.01

52.09

51.66

GlycoMimetics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															52.09	99.70	45.73	48.82	51.66

Competitive Comparison of GlycoMimetics's Cash-to-Debt

For the Biotechnology subindustry, GlycoMimetics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GlycoMimetics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GlycoMimetics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where GlycoMimetics's Cash-to-Debt falls into.

GlycoMimetics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

GlycoMimetics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	41.793	/	(0.742	+	0.067)
	=	51.66

GlycoMimetics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	41.793	/	(0.742	+	0.067)
	=	51.66

GlycoMimetics (NAS:GLYC) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

GlycoMimetics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of GlycoMimetics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

GlycoMimetics (GlycoMimetics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlycoMimetics Inc (NAS:GLYC) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

GKO:Germany

Address

9708 Medical Center Drive, Rockville, MD, USA, 20850

Website

https://www.glycomimetics.com

GlycoMimetics Inc is a clinical stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it plays in inflammation, cancer, and infection.

Executives

Edwin Rock	officer: Chief Medical Officer	9708 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Brian M. Hahn	officer: CFO	C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
Daniel M Junius	director	C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Bruce S Johnson	officer: SVP & Chief Commercial Officer	9708 MEDICAL CENTER DRIVE, BETHESDA MD 20850
Chinmaya Rath	officer: SVP and Chief Business Officer	9708 MEDICAL CENTER DR., ROCKVILLE MD 20850
Invus Public Equities, L.p.	10 percent owner	C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022
Invus Public Equities Advisors, Llc	10 percent owner	C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022
Artal Group S.a.	10 percent owner	VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Artal International S.c.a.	10 percent owner	VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
S.a. Westend	10 percent owner	VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Administratiekantoor Westend Stichting	10 percent owner	CLAUDE DEBUSSYLAAN, 46, AMSTERDAM P7 1082 MD
Artal International Management S.a.	10 percent owner	VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Amaury Wittouck	10 percent owner	VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L2661
Scott D Sandell	10 percent owner
Harout Semerjian	director, officer: Chief Executive Officer	300 THE AMERICAN ROAD, C/O IMMUNOMEDICS, INC., MORRIS PLAINS NJ 07950